Study on Molecular Mechanism about Inhibiting Lung Cancer Cells by Docetaxel Serums from Patients

胡颖,张国玲,李红,李子庭,付士龙,许凯黎

DOI: https://doi.org/10.3781/j.issn.1000-7431.2003.02.003

2003-01-01

Tumor

Abstract:Objective To investigate the molecular events about inhibiting human lung adenocarcinoma cells (SPC-A-1 cell line) by using drug serums from cancer patients in which contained Docetaxel. Methods The apoptosis of SPC-A-1 cells was determined by FCM with AnnexinⅤ-FITC labeling. The expressions of bcl-2, bax and caspase-3 genes were examined by RT-PCR and immunohistochemistry respectively, as well as the enzyme activation of caspase-3 by Western blot. Results (1) A relative higher proportion of apoptosis was observed in SPC-A-1 cells treated with drug serum from patients one hour after the administration of Docetaxel. (2) The expression of bcl-2 gene was obviously lower in the group of cells treated with 1 hour drug serum, while the expression of bax gene was consistent in both treated or untreated groups. The expression rate of bcl-2 to bax gene was decreased significantly in the group of cells treated with 1 hour drug serum than other groups. (3) The m-RNA expression of caspase-3 was not changed in the treated groups, while the activation of caspase-3 was detected by Western blot. Conclusion (1) Drug serum containing Docetaxel can induce apoptosis of SPC-A-1 cells. (2) The expression of bcl-2 gene is involved in the apoptosis of lung cancer cell induced by drug serum in vitro. (3) The molecular event of cell apoptosis may be dependent on the activation of Caspase-3 enzyme rather than the expression of caspase-3 gene.